For research and educational purposes only. Not medical advice.

Articles

Long-form research and education articles from pepSmart on peptides, GLP-1 agonists, SARMs, fitness, sleep, recovery, and longevity. Citation-backed and educational.

Public articles

• Why GLP-1 weight loss plateaus, and what the trials actually show (GLP-1; 9 min read). GLP-1 agonists rarely produce a smooth, monotonic weight curve. The plateau most users hit is biological, not motivational. Here is the receptor and energy-balance story behind it, framed against the published trial data.
• BPC-157, the evidence map: rodent data, human anecdote, and where the gap actually sits (Peptides; 8 min read). BPC-157 has the rare distinction of being widely used and almost entirely uncharacterized in humans. This article maps what is published, what is anecdotal, and what the regulatory posture actually says.
• Peptide storage and stability, the practical, evidence-grounded version (Peptides; 8 min read). Reconstitution diluent, light exposure, freeze-thaw cycles, and lyophilized vs. liquid stability windows. The science underneath the practical questions, and what the published stability literature actually shows.
• SARMs and the regulatory reality: research-only labels do not change legal posture (SARMs; 8 min read). What FDA enforcement, WADA prohibition, and state-level scheduling actually mean for SARMs in 2026, and why the 'research only' label that ships on most products is regulatory cosplay rather than legal cover.
• Sleep architecture and recovery: slow-wave sleep, GH pulses, and what actually moves recovery markers (Sleep; 7 min read). The interesting biology of recovery happens during a specific phase of sleep, not across the night uniformly. Here is what slow-wave sleep does, why GH pulse pattern follows it, and which behavioral levers move the needle in the published literature.
• Injection site rotation, lipohypertrophy, and the skin you cannot see (Peptides; 6 min read). The under-discussed reason injection site rotation matters: subcutaneous tissue remodels under repeated injection, and the remodeling changes how absorption behaves the next time. Here is what the diabetes injection literature shows, and why it generalizes.
• Protein, leucine, and hypertrophy: what the per-meal threshold literature actually says (Fitness; 8 min read). The popular framing of protein and muscle-protein synthesis sits on a real research base, but the practical recommendations are often stronger than the underlying evidence supports. Here is the leucine-threshold story, the bolus-vs-frequency story, and the older trial data.
• VO2max as a longevity marker: what the cohort data actually say, and what they do not (Longevity; 7 min read). VO2max correlates with all-cause mortality across large cohorts. That correlation is real, durable, and replicable, but it is not the same as a causal claim. Here is the difference between association and causation in this literature.
• Mitochondrial density and training: zone 2, biopsy data, and the nuance the popular framing skips (Fitness; 8 min read). The popular framing collapses mitochondrial adaptation to one zone. The biopsy and stable-isotope literature is older, denser, and more nuanced than the podcast version. Here is what the data actually show, and where the disagreement sits.
• NAD precursors, evidence snapshot: NMN, NR, niacin, and what human trials measured (Longevity; 8 min read). NAD biology is fascinating. The supplement implications are murkier than the popular framing. Here is what NMN and NR human trials actually measured, and where they leave the longevity question.
• GLP-1 and muscle loss: lean mass attrition during rapid weight loss, and the levers that actually work (GLP-1; 8 min read). Rapid weight loss costs lean mass. GLP-1 therapies are not unique in this, but the speed and the eating pattern they enforce make it visible faster. Here is what trials actually measured, and what the data say about preserving lean mass.
• Women and peptide research gaps: trial representation, dose interpretation, and where the gap is closing (Research Gaps; 7 min read). Most of the early GLP-1 and peptide pharmacology was characterized in male-skewed cohorts. The downstream consequence is that dose interpretation in women rests on smaller samples than the labeled doses suggest. Here is what the data show, and where the gap is closing.
• Cold exposure and recovery: what the controlled-trial data actually show, and the hypertrophy interaction (Recovery; 7 min read). Cold-water immersion has a long sports-medicine history and a more recent wellness profile. The trial data are not nothing, but they are also not what the popular framing suggests. Here is what controlled work shows, and where it complicates training adaptation.
• Sauna and cardiovascular outcomes: cohort signals, heat-shock biology, and what the trial evidence does and does not show (Recovery; 7 min read). The Finnish KIHD cohort produced the headline sauna numbers. The randomized work fills in some of the picture but cannot answer the causal question by itself. Here is what the data actually support.
• Compounded GLP-1 vs. labeled products: regulatory difference, dosing risk, and what the FDA position actually says (GLP-1; 9 min read). Compounded semaglutide and tirzepatide are not generic versions of the labeled products. They occupy a regulatory gap that the FDA has flagged repeatedly. Here is the regulatory framework, the dosing-error pattern, and what carries over from the trial data and what does not.
• Tesamorelin and visceral fat: what the labeled trial evidence supports, and what it does not (Peptides; 8 min read). Tesamorelin is one of the few peptides with a clear, narrow FDA label and substantial human trial evidence for visceral fat reduction. The off-label conversation runs much wider than the label. Here is what the labeled trials actually showed and where the inference stops.
• Wearable sleep tracking vs. polysomnography: how accurate stage detection actually is, and what your sleep score really measures (Sleep; 7 min read). Wrist wearables show you a sleep architecture chart that looks a lot like polysomnography. The validation literature is more sober: total sleep time is decent, stage detection is rough, and the score on the screen is a blended construct, not a clinical measurement.
• Senolytics in early human trials: what dasatinib plus quercetin and fisetin actually showed, and the senescence-marker problem (Longevity; 8 min read). Senolytic biology is genuinely exciting in animal models. The early human trials are smaller, narrower, and more cautious than the popular framing. Here is what has actually been measured, and the open question of how to even quantify senescence in humans.
• Rapamycin and the off-label longevity conversation: mTOR biology, the dog-aging program, and the dose question (Longevity; 8 min read). Rapamycin is the most-discussed off-label longevity drug in 2026. The animal evidence is robust, the human evidence is thin and mostly indirect, and the dose-and-schedule question is unresolved. Here is what the published trials and mechanism actually support.
• Tirzepatide vs. semaglutide head-to-head: trial differences, dose-response, and what the comparison actually supports (GLP-1; 9 min read). Tirzepatide and semaglutide are the two dominant GLP-1-class agents in 2026. The trials are not perfectly comparable, but a head-to-head exists in type 2 diabetes and the obesity programs sit side by side. Here is what the comparison actually says, and where it stops.